Ask a Question Browse Login

Felodipine Extended-Release Tablets USP Assay

Reference Number: AA-04199 Created: 08/07/2020 04:50 PM Last Updated: 09/05/2020 09:59 AM

Method Conditions:

Column: Cogent RP C18™, 5μm, 100Å
Catalog No.: 68518-15P
Dimensions: 4.6 x 150 mm
Buffer6.9 mg/mL of monobasic sodium phosphate in water. Adjust with 1 M phosphoric acid to a pH of 3.0 ± 0.05
Mobile Phase: Acetonitrile, methanol, and Buffer (40:20:40)
Injection vol.: 40μL
Flow rate: 1.0 mL/min
Detection: 362 nm
Standard solution: 0.02 mg/mL of USP Felodipine in Mobile phase
Peaks: 1. Felodipine

Discussion: This method demonstrates the USP Felodipine Extended-Release Tablet assay in the Cogent RP C18. As shown in the chromatogram with a five injection overlay, the peak efficiency is superb and USP peak tailing guidelines are easily met with the Cogent RP C18™ column. This demonstrates a great alternative column for easy plug and play methods. The Cogent C18 is end-capped and has excellent reproducibility and robustness.

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. 43(6)
Page Information:
USP43-NF38 - 1827
USP42-NF37 – 1787
USP41-NF36 - 1690

Note: Felodipine is a calcium channel blocker and acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. Felodipine prevents myocyte contraction by binding to calcium-binding proteins, which exhibits competitive antagonism of the mineralcorticoid receptor. This event results into inhibiting the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase and blocking calcium influx through voltage-gated T-type calcium channels. This reduces movement of calcium into the cells of the heart and blood vessels and increases supply of blood and oxygen to the heart.

A387.pdf 84.7 Kb Download File
Info Ask a Question 
Your Email: Subject: Question: